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Abstract
Introduction: Angiogenesis and vasculogenesis are critical in rheumatoid arthritis (RA) as they could be a key issue for 
chronic synovitis. Contradictory results have been published regarding circulating endothelial progenitor cells (EPCs) in 
RA. We herein investigated late outgrowth EPC sub-population using recent recommendations in patients with RA and 
healthy controls.
Methods: EPCs, defined as Lin-/7AAD-/CD34+/CD133+/VEGFR-2+ cells, were quantified by flow cytometry in 
peripheral blood mononuclear cells (PBMCs) from 59 RA patients (mean age: 54 ± 15 years, disease duration: 16 ± 11 
years) and 36 controls (mean age: 53 ± 19 years) free of cardiovascular events and of cardiovascular risk factors. 
Concomitantly, late outgrowth endothelial cell colonies derived from culture of PBMCs were analyzed by colony-
forming units (CFUs).
Results: RA patients displayed higher circulating EPC counts than controls (median 112 [27 to 588] vs. 60 [5 to 275]) per 
million Lin- mononuclear cells; P = 0.0007). The number of circulating EPCs positively correlated with disease activity 
reflected by DAS-28 score (r = 0.43; P = 0.0028) and lower counts were found in RA patients fulfilling remission criteria (P 
= 0.0069). Furthermore, late outgrowth CFU number was increased in RA patients compared to controls. In RA, there 
was no association between the number of EPCs and serum markers of inflammation or endothelial injury or synovitis.
Conclusions: Our data, based on a well characterized definition of late outgrowth EPCs, demonstrate enhanced levels 
in RA and relationship with disease activity. This supports the contribution of vasculogenesis in the inflammatory 
articular process that occurs in RA by mobilization of EPCs.
Introduction
Rheumatoid arthritis (RA) is a chronic and destructive
inflammatory disease affecting the joints. RA is now well
known to be associated with striking neovascularization
developed in inflammatory joints [1]. Indeed, angiogenesis,
leading to an increased number of synovial vessels through
local endothelial cells, is a cornerstone of synovial hyper-
plasia occurring in RA. Disturbances in endothelial cell
turnover and apoptosis as well as in angiogenic factors such
as vascular endothelial growth factor (VEGF) have been
reported in RA synovium [2,3]. However, despite the abun-
dant synovial vasculature, there are areas of synovial
hypoxia contributing to synovial and cartilage damage
[4,5]. Hypoxia is highly suggested to activate the angio-
genic cascade, thereby contributing to the perpetuation of
RA synovitis [6].
In addition to angiogenesis issued from resident cells,
cells derived from bone marrow and named circulating
endothelial progenitor cells (EPCs) are able to promote new
blood vessel formation (vasculogenesis) and may therefore
contribute to RA synovitis [7].
EPCs were originally identified by (a) the expression of
markers shared with hematopoietic stem cells such as CD34
and CD133, (b) specific endothelial cell markers such as
KDR (vascular endothelial growth factor receptor-2
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[VEGFR-2] or kinase-insert domain receptor), and (c) their
capacity to differentiate into functional endothelial cells [8-
10]. However, there is no consensus on the precise defini-
tion of EPCs [11]. Evidence showed that there is more than
one endothelial progeny, monocytic versus hemangioblas-
tic, within the circulating blood, and two distinct cell types
of EPCs are currently recognized according to their growth
characteristics and morphological appearance: early-out-
growth EPCs and late-outgrowth EPCs [7,12].
In the currently available human studies, variations in the
level of circulating EPCs were reported in different diseases
affecting the vascular system and were suggested to be a
biomarker for vascular function and tumor progression
[13,14]. In the field of RA, contradictory results have been
reported. Indeed, some studies suggested a lower circulat-
ing EPC number in RA patients compared with controls
[9,10], but conversely, some others reported higher values
[15], and finally some other reports did not find any differ-
ence [8,16]. Several studies have shown an increase of
EPCs within the RA synovial tissue [17,18].
Altogether, these observations underline the difficulty of
accurately quantifying EPC populations. The major issue is
the identification of the different types of circulating
endothelial cells (CECs) issued respectively from the vessel
wall or from bone marrow progenitors. The use of accurate
methods allowing the detection of rare events by flow
cytometry is thus critical. Within this context, our group
contributed to recommendations aiming at the improvement
of EPC detection and characterization [19]. In line with
these latter recommendations and our background in sys-
temic sclerosis [20], we focused on late-outgrowth EPCs
that represent the progenitors with the more genuine
endothelial properties. In parallel to EPCs, CECs detached
from vessel walls (CECs) may also be a relevant biomarker
of vascular disease. We hypothesized that coupled raised
levels of these two populations may reflect the vascular sta-
tus of the disease and thus represent innovative biomarkers.
Therefore, our aims were (a) to enumerate EPCs and late-
outgrowth endothelial colony formation in RA patients and
controls, (b) to assess correlations between EPC counts,
CEC counts, and RA activity, and (c) to correlate EPC and
CEC counts with levels of serum markers of synovitis or
endothelial injury.
Materials and methods
Patients
The study involved 59 RA patients (54 females; mean age
of 54 ± 15 years) fulfilling the RA American College of
Rheumatology criteria [21]. RA patients were consecu-
tively enrolled during a 6-month period regardless of dis-
ease activity and underwent a routine clinical examination
that included the calculation of 28-joint disease activity
score (DAS-28). The patients' characteristics are summa-
rized in Table 1. Ongoing biologic therapies included tumor
necrosis factor (TNF) blockers (etanercept, adalimumab, or
infliximab) in 11 patients and anti-CD20 (rituximab) in 12
patients. Thirty-six healthy volunteers (26 females; mean
age of 53 ± 19 years) coming from our first study served as
controls [20]. Exclusion criteria for all subjects were car-
diovascular events and conventional cardiovascular risk
factors (diabetes, hypertension, and past medical history of
coronary artery disease and smoking) except for three RA
patients with controlled systemic hypertension. None of the
patients had been treated previously with statins, a drug
Table 1: Rheumatoid arthritis study population
Laboratory and clinical 
data
RA patients (n = 59)
Disease duration in days, 
mean ± SD
16 ± 11
Erosive RA, number 
(percentage)
54 (92)
Positive rheumatoid factor, 
>10 IU, ELISA, number 
(percentage)
52 (88)
Positive anti-CCP antibodies, 
>10 IU, ELISA, number 
(percentage)
52 (88)
ESR in mm/hour, mean ± SD; 
ESR >28, number 
(percentage)
28 ± 21; 35 (59)
CRP in mg/dL, mean ± SD; 
CRP >15, number 
(percentage)
25 ± 41; 23 (39)
DAS-28, mean ± SD 4.36 ± 1.7
DAS-28 < 2.6, number 
(percentage)
11 (19)
2.6 < DAS-28 < 5.1, 
number (percentage)
21 (35)
DAS-28 > 5.1, number 
(percentage)
27 (46)
Methotrexate, number 
(percentage)
49 (83)
Low dose of prednisone, ≤10 
mg/day, number 
(percentage)
54 (92)
Anti-tumor necrosis factor 
agents, number (percentage)
11 (17)
Anti-CD20 agents, number 
(percentage)
12 (20)
anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive 
protein; DAS-28, 28-joint disease activity score; ELISA, enzyme-
linked immunosorbent assay; ESR, erythrocyte sedimentation 
rate; RA, rheumatoid arthritis; SD, standard deviation.Jodon de Villeroché et al. Arthritis Research & Therapy 2010, 12:R27
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known to be associated with increased EPC levels [22,23].
All patients and volunteers gave informed consent for all
procedures, which were carried out with local ethics com-
mittee approval Comité de Protection des Personnes, Ile de
France III (CPPP IDF III).
Flow cytometry quantification
EPCs were quantified by fluorescence-activated cell sorting
(FACS) as previously described [20]. Briefly, peripheral
blood mononuclear cells (PBMCs) were first depleted of
positive lineage mononuclear cells (CD2+, CD3+, CD14+,
CD16+, CD19+, CD24+, CD56+, and CD66b+  cells) by
human progenitor cell enrichment cocktail (RosetteSep®;
StemCell Technologies, Vancouver, BC, Canada), and sec-
ondly subjected to triple-labelling with anti-CD133-phyco-
erythrin (PE) (Miltenyi Biotec, Paris, France), anti-
VEGFR-2 (KDR)-allophycocyanin (APC) (R&D Systems,
Minneapolis, MN, USA), and anti-CD34 or anti-CD105-
fluorescein isothiocyanate (FITC) (BD Biosciences, Le
Pont de Claix, France) antibodies. A preincubation of an
FcR-blocking reagent (Miltenyi Biotec) was performed to
inhibit non-specific binding, and identical IgG isotypes
served as negative controls. Third, viable PBMCs were dis-
criminated by 7-aminoactinomycin D (7AAD) labelling.
The EPC and CEC populations were finally identified as
Lin-/7AAD-/CD34+/CD133+/VEGFR-2+  cells and Lin-/
7AAD-/CD105+/CD133-/VEGFR-2+ cells, respectively. At
least 500,000 events were analyzed, and results were
expressed as the number of EPCs or CECs per million Lin-
mononuclear cells.
Endothelial progenitor cell quantification by late-
outgrowth colony-forming unit assay
In 53 RA patients and 35 controls with FACS quantifica-
tion, we used a method of culture suitable for isolating late-
outgrowth EPC-derived colonies [20]. The blood mononu-
clear cell fraction was collected by Ficoll (Pancoll, Dutcher,
France) density gradient centrifugation and was resus-
pended in endothelial growth medium (EGM-2) (Lonza,
Verviers, Belgium). Cells were then seeded on collagen-
precoated 12-well plates (BD Biosciences) at 2 × 107 cells
per well and stored at 37°C and 5% CO2. After 24 hours of
culture, adherent cells were washed once with phosphate-
buffered saline 1x and cultured in EGM-2 with daily
changes until the quantification. Colonies of endothelial
cells appeared between 9 and 26 days of culture and were
identified as well-circumscribed monolayers of cells with a
cobblestone appearance. EPC colonies were counted visu-
ally under an inverted microscope (Olympus, Paris,
France).
Enzyme-linked immunosorbent assays
In a random subgroup of 49 patients with RA and 10
healthy controls, levels of serum soluble vascular cell adhe-
sion molecule-1 (sVCAM), stromal-derived factor-1 (SDF-
1), human cartilage glycoprotein-39 (YKL-40), and carti-
lage oligomeric matrix protein (COMP) -- markers of
endothelial injury, progenitor mobilization, synovitis, and
synovitis, respectively -- were measured by enzyme-linked
immunosorbent assay (R&D Systems; Kamiya Biomedical
Company, Seattle, WA, USA; and Quidel Corporation, San
Diego, CA, USA) in accordance with the manufacturers'
instructions.
Data analysis
All data are presented as median (range) unless otherwise
stated. Comparisons were performed by non-parametric
Mann-Whitney, Kruskal-Wallis, or Spearman rank correla-
tion (r) tests, when appropriate. The chi-square test was
used to compare categorical variables. P values are two-
tailed, and P values of not more than 0.05 were considered
statistically significant.
Results
Endothelial progenitor cell and circulating endothelial cell 
levels in rheumatoid arthritis
EPC level (Lin-/7AAD-/CD34+/CD133+/VEGFR-2+) was
significantly higher in RA patients than in controls (112 [27
to 588] versus 60 [5 to 275] EPCs; P = 0.0007) (Table 2 and
Figure 1a). The two Lin-/7AAD-/CD133+/VEGFR-2+ and
Lin-/7AAD-/CD34+/VEGFR-2+  subpopulations were also
significantly higher in RA patients (Table 2). The CEC pop-
ulation (Lin-/7AAD-/CD105+/CD133-/VEGFR-2+  cells)
was increased in RA patients compared with controls,
although this did not reach statistical significance (Table 2
and Figure 1b). The CEC and EPC levels in RA patients as
well as in controls were correlated (r = 0.43 and 0.74, P =
0.003 and 0.0015, respectively) (Figure 2).
Association between endothelial progenitor cell levels and 
disease activity
In RA patients, EPC levels correlated with DAS-28 (r =
0.43, P = 0.003, Spearman test) (Figure 3a). In addition,
EPC levels were significantly decreased in patients fulfill-
ing DAS-28 remission criteria when compared with moder-
ate (2.6 < DAS-28 < 5.1) or high (DAS-28 >5.1) activities
(P = 0.007, Kruskal-Wallis test) (Figure 3b). No association
was found between EPC levels and high values of erythro-
cyte sedimentation rate (ESR) (>28) (P = 0.9) or between
EPC levels and high values of C-reactive protein (>15) (P =
0.7). Swollen joint counts did not correlate with EPC values
(r = 0.23, P = 0.99). There was no association between EPC
number and age, disease duration, and other disease fea-
tures, including treatments (low doses of corticosteroids
and methotrexate). In regard to biologic therapy, patients
receiving TNF blockers or anti-CD20 did not have different
EPC levels (median [range] 88 [27 to 529], P = 0.9922 and
83.5 [33 to 345], P = 0.1906, respectively). Likewise, CECJodon de Villeroché et al. Arthritis Research & Therapy 2010, 12:R27
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levels did not correlate with RA characteristics or treat-
ments.
Number of late-outgrowth endothelial progenitor cell 
colony-forming units in rheumatoid arthritis
Endothelial colony formation has previously been used as
an alternative method to detect endothelial progenitors in
PBMCs [20]. CFU assays were performed in association
with FACS quantification in 53 RA patients and 35 con-
trols. EPC-CFUs appeared at the ninth day of PBMC cul-
ture at the earliest and were confirmed by a typical
morphology of a well-delineated colony of cells with a cob-
blestone appearance (Figure 4a). The percentage of RA
patients displaying EPC colony formation was significantly
higher than that of controls (74% versus 57%; P = 0.029) in
accordance with their higher EPC levels (118.5 [29 to 588]
versus 84 [19 to 275]; P = 0.049). Furthermore, comparison
of the mean number of EPC-CFUs measured in RA patients
and controls revealed an increase in CFU number in RA
patients (3.4 ± 0.7 versus 2 ± 0.5; P = 0.048) (Figure 4b). In
the RA population, CFU numbers correlated with none of
RA characteristics or treatments.
Lack of association between serum markers and 
endothelial progenitor cell levels
Different serum markers -- including sVCAM (677 [294 to
2,624] versus 512 [371 to 738] ng/mL; P = 0.018), YKL-40
(88 [24 to 256] versus 50 [15 to 59] ng/mL; P = 0.0029),
and COMP (2.4 [1.2 to 4.4] versus 1.3 [0.8 to 1.5] μg/mL; P
< 0.0001) -- were found to be significantly increased in RA
patients as compared with healthy controls. There was no
significant difference for SDF-1 concentration (3,690 [73 to
6,973] versus 3,562 [1,540 to 6,451] pg/mL). However, val-
ues of EPCs in RA patients were unrelated to any of the
above serum markers. Also, CEC levels were not linked
with serum markers of synovitis but were significantly
higher in RA patients with a high sVCAM level (>1,000 ng/
mL; P = 0.0035).
Figure 1 Endothelial progenitor cell (EPC) and circulating endothelial cell (CEC) levels in rheumatoid arthritis (RA) patients compared with 
controls (cells per 106 lineage-negative [Lin-] mononuclear cells). (a) Higher EPC levels (Lin-7AAD-CD34+CD133+VEGFR-2+) in RA patients (n = 59) 
than in controls (n = 36) (P < 0.001). (b) No significant difference between CEC levels (Lin-7AAD-CD105+CD133-VEGFR-2+) in RA patients (n = 59) and 
controls (n = 15). 7AAD, 7-aminoactinomycin D; VEGFR-2, vascular endothelial growth factor receptor-2.
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Figure 2 Positive correlation between endothelial progenitor cell (EPC) counts and circulating endothelial cell (CEC) counts (cells per 106 
lineage-negative mononuclear cells). (a) Patients with rheumatoid arthritis. (b) Controls. Correlation coefficient r and P values are indicated.
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Discussion
Our results obtained by using a well-characterized defini-
tion of late-outgrowth EPCs in a relatively large number of
patients show enhanced levels of this cell population and
relationships with RA disease activity. Available data have
reported conflicting results about the EPC counts in this
inflammatory condition. Several methodological issues
could explain such discrepancies. We herein followed
recent recommendations and used a previously validated
method for late-outgrowth EPC enumeration [20].
The quantification of EPCs by flow cytometry first
requires enrichment techniques to select a correct number
of this scarce population and a specific marker combination
to select the subpopulation of hemangioblastic EPCs. In
culture, these 'true' angioblast-like EPCs are represented by
cells that enable late outgrowth with higher proliferative
potential, while endothelial cell colonies that appear early
might more preferentially originate from monocytes or
CECs [11,24]. In the study herein, we excluded the mono-
cytic EPC subpopulation from the quantification and thus
selected hemangioblastic EPCs by the lineage-positive cell
depletion including CD14+ cells. We also extended the cir-
culating EPC definition with an additional marker of viabil-
ity to select non-apoptotic cells. One may suggest that the
several steps required by our technique may induce proce-
dural loss of progenitors which are prone to undergo apop-
tosis. However, the controlled design of our study limits
this potential bias but this will need additional work. In par-
allel, EPC counts were also determined by the selection in
culture of the late-outgrowth EPCs according to the delays
before their appearance.
None of the previous studies that reported EPC levels in
RA patients was based on these methods. The previous data
quantified, conversely to our study, circulating EPCs in
whole blood with only three surface markers (CD34/
CD133/VEGFR-2) [8-10,16]. These authors also assessed
EPC-CFU numbers, focusing on the 'early outgrowth' sub-
population and finding or not finding results consistent with
those of flow cytometry quantification. These methodologi-
cal differences may account for the discrepancy with regard
Table 2: Absolute number of stem cells and circulating endothelial progenitor cells in peripheral blood (cells per 106 
lineage-negative mononuclear cells)
Cells per 106 Lin-
mononuclear cells
RA patients (n = 59) Controls (n = 36) P value
Lin-/7AAD-/CD34+/CD133+ 0.0002
Median (range) 2,484 (213-26,613) 1,068 (123-2,270)
25%-75% percentile 1,141-5,943 610.5-1,575
Lin-/7AAD-/CD34+/VEGFR-2+ 0.0026
Median (range) 259 (27-588) 103 (11-1,105)
25%-75% percentile 124-493 49.75-193.8
Lin-/7AAD-/CD133+/VEGFR-2+ 0.0276
Median (range) 151 (45-964) 125 (25-555)
25%-75% percentile 93-387 99.25-192.8
Lin-/7AAD-/CD34+/CD133+/
VEGFR-2+ (EPCs)
0.0007
Median (range) 112 (27-588) 60 (5-275)
25%-75% percentile 53-227 26-109.8
Lin-/7AAD-/CD105+/CD133-/
VEGFR-2+(CECs)
0.1727
Median (range) 173 (12-989) 139 (30-426)a
25%-75% percentile 57-341 73-189
Ratio EPCs/CECs, median 
(range)
1 (0.07-4.28) 1 (0.2-2.02)a 0.3946
aCirculating endothelial cell (CEC) number has been evaluated in 15 healthy controls. 7AAD, 7-aminoactinomycin D; DAS-28, 28-joint disease 
activity score; EPC, endothelial progenitor cell; Lin-, lineage-negative; RA, rheumatoid arthritis; VEGFR-2, vascular endothelial growth factor 
receptor-2.Jodon de Villeroché et al. Arthritis Research & Therapy 2010, 12:R27
http://arthritis-research.com/content/12/1/R27
Page 6 of 8
to our results. Indeed, differences between the various EPC
studies may not relate to the characteristics of the RA popu-
lation enrolled. Our population of RA patients, issued from
consecutive inclusions, did not display differences with
other studies based on criteria known to modulate EPC lev-
els -- such as age (mean of 53 to 59 years) and frequency of
use of methotrexate or low doses of corticosteroids -- or on
the choice to exclude patients with previous cardiovascular
events [25-27]. In addition, it is noteworthy that EPC
counts did not differ according to the use of biologics,
although the cross-sectional design limits the analysis of the
influence of such therapies in our RA patients. The only
specificity of our RA patients may be the relatively long
disease duration in comparison with other works. Neverthe-
less, disease duration was never reported to be associated
with EPC levels and thus may not account for our findings.
We excluded RA patients with cardiovascular risk factors in
order to rule out the bias of the specific effects of atheroma
on EPC counts and thus to focus on relationships between
disease activity and EPC counts as this has been done in
many previous studies [9,10]. One may suggest that this
may have introduced a selection bias and the use of this
exclusion criterion may have obscured a negative influence
of cardiovascular risk factors on EPC counts.
We herein provide the demonstration of the identification
of the late-outgrowth subset by the association between cir-
culating cell counts and culture isolations. Indeed, two dif-
ferent subpopulations of EPCs, namely early and late EPCs,
Figure 3 Associations of endothelial progenitor cell (EPC) levels in rheumatoid arthritis (RA) with disease activity. Correlation between EPC 
counts and disease activity (a) and association of lower EPC levels in different groups of RA patients according to disease activity score (P < 0.01) (b). 
7AAD, 7-aminoactinomycin D; DAS-28, 28-joint disease activity score; Lin-, lineage-negative; VEGFR-2, vascular endothelial growth factor receptor-2.
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Figure 4 Late-outgrowth endothelial progenitor cell colony-forming unit (CFU) number in rheumatoid arthritis (RA) patients and controls. 
(a) Representative photomicrograph of late-outgrowth CFUs in culture after 15 days from one RA patient (×40 magnification). (b) Increase of CFU 
number in RA patients (P < 0.05).
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can be derived from peripheral blood depending on the dif-
ferent culture methods and times [24,28]. Although both
EPCs express endothelial markers, they have different mor-
phologies, patterns of growth, and angiogenic properties
and thus might have different roles in neovasculogenesis
[24,29-31]. Late-outgrowth EPCs that represent the progen-
itors with the more genuine endothelial properties such as
tube-forming activity in vitro and in vivo need to be better
characterized in the context of inflammatory conditions.
Previously, the late EPC subpopulation has been studied in
systemic sclerosis by our group and their endothelial prop-
erties confirmed by angiogenic tests [32]. As reported in
systemic sclerosis, we observed that the RA patients, hav-
ing high Lin-7AAD-CD34+CD133+VEGFR-2+, displayed a
higher number of EPC-CFUs. However, the size of the sam-
ple reduced by the non-systematic achievement of EPC-
CFUs could explain the limited increase of EPC-CFU num-
bers in RA patients as well as the lack of association with
disease activity and will need larger studies.
W e thus assume that our EPC definition allows a well-
characterized quantification of late-outgrowth EPCs. In
RA, our data support the contribution of late-outgrowth
EPCs to synovitis according to our finding of a strong link
with disease activity. The direct correlation of EPC counts
with DAS-28 levels is strengthened by the fact that RA
patients in remission displayed EPC levels comparable to
those of controls. Together with evidence of CD133/
VEGFR-2+ cells in RA synovial tissue [17], our results
emphasize a key role for vasculogenesis and EPC mobiliza-
tion in RA.
Preliminary data on CEC outcome in vascular diseases
have suggested a relationship between the detachment of
mature CECs and vascular hurting [33]. We concomitantly
determined the value of CECs as compared with EPCs. We
found a correlation in RA between these two circulating
cell levels but CEC levels in RA did not differ for the ones
in controls. Using a CD146 immunoselection in whole
blood, one study found enhanced CEC levels but failed to
identify a specific association with blood inflammatory
markers [34]. The best combination of surface markers
including exclusion of dead cells by viability marker seems
to be required for CEC quantification.
One of the pitfalls of EPC quantification in RA is the
potential involvement of atherosclerosis in EPC changes
[35,36]. However, we excluded from our study individuals
with classical cardiovascular risk factors and also those
with previous clinical events. Furthermore, we did not find
an increase of CEC levels in our RA population which
reflects endothelial injury. Indeed, we presume that EPC
increase relates to RA disease activity and synovial inflam-
mation, although measurement of infra-clinical atheroma
would be necessary to definitely rule out endothelial dys-
function.
We then attempted to correlate EPC counts with blood
markers reflecting inflammation (ESR), endothelium injury
(sVCAM), or synovial involvement (COMP and YKL-40).
While we failed in the identification of any link, sVCAM,
COMP, and YKL-40 were found to be increased in RA
patients, thus confirming the activity of the disease in our
sample of RA patients. We assume that, despite the lack of
a link with serum markers, the identification of a relation-
ship between EPCs and DAS-28 is highly relevant. EPC
count is probably influenced by several factors, including
inflammation, vascular injury, and potentially the immune
response with bone marrow changes. The multifactorial
regulation probably precludes the identification of a corre-
lation with one single serum marker. Therefore, EPCs could
represent a new 'integrative' biomarker. Its predictive value
on disease outcome, including both articular and cardiovas-
cular issues, will have to be evaluated in upcoming pro-
spective studies.
Conclusions
We demonstrate enhanced levels of late-outgrowth EPCs in
RA and a relationship with disease activity. This supports
the implication of vasculogenesis in the perpetuation of the
synovitis that occurs in RA. Late-outgrowth EPC isolation
also offers a unique opportunity to determine an RA
endothelial signature.
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